Literature DB >> 32472359

Reentry to Metabolic and Bariatric Surgery During the COVID19 Pandemic.

Abdelrahman A Nimeri1,2, Brent D Matthews3.   

Abstract

Patients with obesity and diabetes have higher risk for severe complications and mortality from COVID19 infection. In addition, unexpected mortalities were reported in a small series of asymptomatic COVID19-positive patients undergoing metabolic and bariatric surgery (MBS). Several organization including IFSO and the American College of Surgeons (ACS) endorsed recommendations to suspend elective nonessential surgery including MBS during the peak period of COVID19. However, both recommendations have no clear guidelines on how to prioritize MBS patients after the peak of COVID19 cases has passed, but there remain patients with asymptomatic COVID19 in the community. We present a tiered approach to restart MBS during the COVID19 pandemic once the peak of new cases has passed or the curve of new COVID19 cases has flattened.

Entities:  

Keywords:  COVID19 pandemic; Re-entry to metabolic and bariatric surgery

Mesh:

Year:  2020        PMID: 32472359     DOI: 10.1007/s11695-020-04736-5

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  2 in total

1.  Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis.

Authors:  Ashish Kumar; Anil Arora; Praveen Sharma; Shrihari Anil Anikhindi; Naresh Bansal; Vikas Singla; Shivam Khare; Abhishyant Srivastava
Journal:  Diabetes Metab Syndr       Date:  2020-05-06

2.  Recommendations for Metabolic and Bariatric Surgery During the COVID-19 Pandemic from IFSO.

Authors:  Wah Yang; Cunchuan Wang; Scott Shikora; Lilian Kow
Journal:  Obes Surg       Date:  2020-06       Impact factor: 4.129

  2 in total
  1 in total

1.  Bariatric surgery for metabolic unhealthy obesity (MUO) during the COVID era: short-term results of a high-volume center.

Authors:  Valeria Guglielmi; Michela Campanelli; Emanuela Bianciardi; Domenico Benavoli; Luca Colangeli; Monica D'Adamo; Paolo Sbraccia; Paolo Gentileschi
Journal:  Eat Weight Disord       Date:  2022-07-19       Impact factor: 3.008

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.